BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28368800)

  • 1. [Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for oocyte donors].
    Benchabane M; Santulli P; Maignien C; Bourdon M; De Ziegler D; Chapron C; Gayet V
    Gynecol Obstet Fertil Senol; 2017 Feb; 45(2):83-88. PubMed ID: 28368800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
    Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B;
    Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
    Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
    Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
    Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
    Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of corifollitropin alfa/GnRH antagonist protocol combined with GnRH agonist triggering and freeze-all strategy in polycystic ovary syndrome patients.
    Hwang JL; Chen SU; Chen HJ; Chen HF; Yang YS; Chang CH; Seow KM; Tzeng CR; Lin YH
    J Formos Med Assoc; 2018 Jun; 117(6):535-540. PubMed ID: 28830648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF.
    Fauser BC; Alper MM; Ledger W; Schoolcraft WB; Zandvliet A; Mannaerts BM;
    Reprod Biomed Online; 2010 Nov; 21(5):593-601. PubMed ID: 20843746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the safety and efficacy of corifollitropin alfa combined with GnRH agonist triggering in oocyte donation cycles. A prospective longitudinal study.
    Tsakiridis I; Najdecki R; Tatsi P; Timotheou E; Kalinderi K; Michos G; Virgiliou A; Yarali H; Athanasiadis A; Papanikolaou EG
    JBRA Assist Reprod; 2020 Oct; 24(4):436-441. PubMed ID: 32489086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis.
    Fensore S; Di Marzio M; Tiboni GM
    J Ovarian Res; 2015 Jun; 8():33. PubMed ID: 26036214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol.
    Devroey P; Boostanfar R; Koper NP; Mannaerts BM; Ijzerman-Boon PC; Fauser BC;
    Hum Reprod; 2009 Dec; 24(12):3063-72. PubMed ID: 19684043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization.
    Devroey P; Fauser BC; Platteau P; Beckers NG; Dhont M; Mannaerts BM
    J Clin Endocrinol Metab; 2004 May; 89(5):2062-70. PubMed ID: 15126522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol.
    Fatemi HM; Doody K; Griesinger G; Witjes H; Mannaerts B
    Hum Reprod; 2013 Feb; 28(2):442-52. PubMed ID: 23136144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corifollitropin alfa compared to daily rFSH or HP-HMG in GnRH antagonist controlled ovarian stimulation protocol for patients undergoing assisted reproduction.
    Souza PMG; Carvalho BR; Nakagawa HM; Rassi TRE; Barbosa ACP; Silva AA
    JBRA Assist Reprod; 2017 Jun; 21(2):67-69. PubMed ID: 28609269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corifollitropin alfa: a review of its use in controlled ovarian stimulation for assisted reproduction.
    Croxtall JD; McKeage K
    BioDrugs; 2011 Aug; 25(4):243-54. PubMed ID: 21815699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study.
    Polyzos NP; De Vos M; Corona R; Vloeberghs V; Ortega-Hrepich C; Stoop D; Tournaye H
    Hum Reprod; 2013 May; 28(5):1254-60. PubMed ID: 23442756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta-analysis.
    Mahmoud Youssef MA; van Wely M; Aboulfoutouh I; El-Khyat W; van der Veen F; Al-Inany H
    Fertil Steril; 2012 Apr; 97(4):876-85. PubMed ID: 22277766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle-stimulating hormone.
    Boostanfar R; Mannaerts B; Pang S; Fernandez-Sanchez M; Witjes H; Devroey P;
    Fertil Steril; 2012 Jun; 97(6):1351-8. PubMed ID: 22459628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of corifollitropin alfa on Day 2 versus Day 4 of the cycle in a GnRH antagonist protocol: a randomized controlled pilot study.
    Blockeel C; Polyzos NP; Derksen L; De Brucker M; Vloeberghs V; van de Vijver A; De Vos M; Tournaye H
    Hum Reprod; 2014 Jul; 29(7):1500-7. PubMed ID: 24813196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the follicular output rate after controlled ovarian stimulation with daily recombinant follicle-stimulating hormone versus corifollitropin alfa.
    Griesinger G; Teal V; McCrary Sisk C; Ruman J
    Eur J Obstet Gynecol Reprod Biol; 2019 Jan; 232():101-105. PubMed ID: 30529793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors for ovarian response in a corifollitropin alfa/GnRH antagonist protocol for controlled ovarian stimulation in IVF/ICSI cycles.
    Oehninger S; Nelson SM; Verweij P; Stegmann BJ
    Reprod Biol Endocrinol; 2015 Oct; 13():117. PubMed ID: 26520396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corifollitropin alfa followed by rFSH in a GnRH antagonist protocol for poor ovarian responder patients: an observational pilot study.
    Polyzos NP; Devos M; Humaidan P; Stoop D; Ortega-Hrepich C; Devroey P; Tournaye H
    Fertil Steril; 2013 Feb; 99(2):422-6. PubMed ID: 23084565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.